NDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEOCILLIN is an oral, small-molecule penicillin antibiotic (carbenicillin indanyl sodium) approved in 1972 for treating bacterial infections, primarily urinary tract and prostate infections. It is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
LOE Approaching
As LOE approaches, GEOCILLIN likely operates with a small, specialized team focused on maintaining existing market share rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GEOCILLIN offers career value primarily in defensive commercial and operational roles; professionals should expect focus on generic mitigation, market access, and cost management rather than innovation or growth strategy. This role is best suited for those seeking to develop expertise in product lifecycle management and mature brand stewardship within a legacy portfolio.
Brand Manager
Worked on GEOCILLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.